A. Photochemotherapy (methoxsalen with long wave UVA radiation) is indicated for the symptomatic control
of severe, recalcitrant, disabling psoriasis not adequately responsive to other forms of therapy and when the
diagnosis has been supported by biopsy. Photochemotherapy is intended to be administered only in conjunction
with a schedule of controlled doses of long wave ultraviolet radiation.
B. Photochemotherapy (methoxsalen with long wave ultraviolet radiation) is indicated for the repigmentation
of idiopathic vitiligo.
C. Photopheresis (methoxsalen with long wave ultraviolet radiation of white blood cells) is indicated for use
with the UVAR System in the palliative treatment of the skin manifestations of cutaneous T-cell
lymphoma (CTCL) in persons who have not been responsive to other forms of treatment. While this
dosage form of methoxsalen has been approved for use in combination with photopheresis.
